ClinConnect ClinConnect Logo
Search / Trial NCT06234670

Risk Factors and A Prediction Model of Recurrence of Uterine Fibroids

Launched by WENWEN WANG · Jan 28, 2024

Trial Information

Current as of June 12, 2025

Not yet recruiting

Keywords

Uterine Fibroid Recurrence Risk Factor Prediction Medel

ClinConnect Summary

This clinical trial is looking to understand why some women experience a recurrence of uterine fibroids after treatment and to develop a prediction model that can help identify those at higher risk. Uterine fibroids are non-cancerous growths in the uterus that can cause various symptoms. The goal of the study is to find ways to detect these recurrences early, so that doctors can intervene sooner and provide better care for patients who might be affected.

To participate in this trial, women must be between the ages of 18 and 50 and have been diagnosed with uterine fibroids through imaging tests like ultrasound. They must also be willing to undergo a surgical procedure called myomectomy to remove the fibroids. However, women with severe infections, a history of cancer, incomplete medical records, or who are pregnant cannot participate. If you qualify, you can expect to contribute valuable information that could help future patients dealing with similar issues.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age:18-50 years
  • 2. Diagnosed with uterine fibroids (by ultrasound or pathology)
  • 3. Accept myomectomy.
  • 4. Complete clinical data.
  • Exclusion Criteria:
  • 1. Severe infectious disease
  • 2. Previous history of malignant tumors
  • 3. Incomplete clinical data.
  • 4. Pregnant

About Wenwen Wang

Wenwen Wang is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic interventions. With a focus on rigorous study design and ethical standards, Wenwen Wang leads initiatives that encompass a wide range of therapeutic areas. The sponsor prioritizes collaboration with research institutions and healthcare professionals to ensure the integrity and efficacy of clinical trials. Through meticulous planning and execution, Wenwen Wang aims to contribute valuable insights to the scientific community and enhance the development of safe and effective treatments.

Locations

Wuhan, None Selected, China

Patients applied

0 patients applied

Trial Officials

Shixuan Wang, Phd

Study Chair

Huazhong University of Science and Technology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported